Recent advances in dengue pathogenesis and clinical management  by Simmons, Cameron P. et al.
RC
P
a
b
c
d
e
f
a
A
A
K
D
V
P
I
V
C
1
f
p
p
t
t
d
n
v
(
a
e
o
T
a
a
i
m
T
T
h
0Vaccine 33 (2015) 7061–7068
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
ecent  advances  in  dengue  pathogenesis  and  clinical  management
ameron  P.  Simmonsa,b,c,∗, Kirsty  McPhersonc,  Nguyen  Van  Vinh  Chaud, D.T.  Hoai  Tame,
aul  Youngf,  Jason  Mackenziec, Bridget  Willsa,b
Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet street, District 5, Ho Chi Minh City, Viet Nam
Centre for Tropical Medicine, Nufﬁeld Department of Medicine, University of Oxford, Oxford, United Kingdom
Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia
Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Viet Nam
University of Medicine and Pharmacy, 217 Hong Bang, District 5, Ho Chi Minh City, Viet Nam
School of Chemistry and Molecular Biosciences, University of Queensland, Australia
 r  t  i  c  l  e  i  n  f  o
rticle history:
vailable online 14 October 2015
a  b  s  t  r  a  c  t
This  review  describes  and  commentates  on  recent  advances  in  the  understanding  of  dengue  pathogenesis
and  immunity,  plus  clinical  research  on vaccines  and therapeutics.  We  expand  speciﬁcally  on  the  role
of the  dermis  in  dengue  virus  infection,  the contribution  of cellular  and  humoral  immune  responses  toeywords:
engue
accine
athogenesis
mmunology
irology
pathogenesis  and  immunity,  NS1 and  mechanisms  of  virus  immune  evasion.  Additionally  we review a
series  of  therapeutic  intervention  trials  for  dengue,  as  well  as  recent  clinical  research  aimed  at  improving
clinical  diagnosis,  risk  prediction  and  disease  classiﬁcation.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).linical research
. Introduction
The underlying mechanistic causes of the dominant clinical
eatures of severe dengue, i.e. a transient increase in vascular
ermeability and a hemorrhagic diathesis, remain enigmatic. In
rinciple, acquiring deeper insights into the mechanistic drivers of
he clinically important features of dengue should enable improved
reatment strategies and uncover novel drug targets. Yet neatly
issecting the pathogenesis of any infectious disease syndrome is
ever straightforward and dengue is no exception. Host and virus
ariables shape the clinical outcome of any given dengue virus
DENV) infection. For the host, there is undoubtedly a physiological
nd immunological component (humoral and cellular) that inﬂu-
nces whether infection (or re-infection) has a benign outcome
r results in disease that manifests across a gradient of severity.
here must also be a virological aspect, such that some viruses
re simply better equipped to replicate and reach high titers in human (or mosquito) host. Neither of these processes work in
solation. Rather, the outcome of exposure to an infectious Aedes
osquito will always depend on a constellation of “positive” and
∗ Corresponding author at: Oxford University Clinical Research Unit, Hospital for
ropical Diseases, 764 Vo Van Kiet street, District 5, Ho Chi Minh City, Viet Nam.
el.: +84 904434839.
E-mail address: csimmons@oucru.org (C.P. Simmons).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.103
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u“negative” host and viral factors that each inﬂuences the over-
all clinical evolution of the infection. Layered upon this are the
beneﬁts that careful clinical management can have in preventing
or treating the life-threatening complications that may  occur; in
many endemic countries improvements in clinical management
mean that case fatality rates amongst hospitalized cases have been
reduced from 20% to less than 0.5%. Yet there is still room to do
better. This might be via development of more effective, evidence-
based ﬂuid resuscitation strategies for cases with severe shock, or
the arrival of speciﬁc anti-viral therapeutics or disease modiﬁers
able to reduce the duration and/or severity of generalized symp-
toms in the tens of millions of uncomplicated dengue cases that
occur globally. Central to all considerations of patient-centered
research ﬁndings in dengue is an understanding of the temporal
“windows” that exist in the evolution of disease. These “windows”
are represented schematically in Fig. 1. Beyond all else, they under-
score the dynamic nature of disease evolution and that clinical
research studies must always consider timing of interventions,
observations and sampling in their design and reporting.
Following the bite of an infected mosquito the virus dissem-
inates and infects multiple lymphoid and non-lymphoid tissues.
A viremia ensues that is presumed to be a proxy for the under-
lying severity of tissue infection. The viral burden accumulates
to the point that generalized clinical symptoms (fever, headache,
myalgia) develop, presumably secondary to a host antiviral state
in which interferon expression is abundant. Viremia peaks shortly
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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fter fever onset (day 0) and then plateaus for 1–2 days before grad-
ally declining, driven by the host adaptive immune response. By
he 4–6th day of illness the fever breaks in most patients and symp-
oms recede. Increased capillary permeability, often subclinical, is
easurable in many patients during the critical phase, with likely
nset during the febrile phase. The increased permeability, coag-
lopathy, thrombocytopenia and other laboratory derangements
re most pronounced around the time of defervescence, and this
s the timepoint where most of the severe complications manifest.
uring the recovery phase there is gradual normalization of clinical
nd laboratory features. Activated T cells and increasing concentra-
ions of DENV reactive IgM and IgG are detected toward the end of
he febrile phase and during the recovery phase.
. Pathogenesis
.1. Initiation of DENV infection: is the dermis an important site
f virus infection?
Since the ﬁrst description of DENV infection of dendritic cells
DCs) in cadaveric human skin explants [1], there has been grow-
ng interest in this aspect of the DENV-host interaction. Recent
esearch interest has focused on DENV infection of dendritic cell
opulations (DCs) that are resident in the skin, plausibly the ﬁrst
natomic location where DENV interacts with key actors in the
uman immune system when the virus is delivered via the pro-
ing of an infected mosquito. In vitro, Cerny et al. [2] challenged
ingle cell suspensions derived from human skin with cultured
ENV and detected productive infection of CD14(+) and CD1c(+)
Cs, Langerhan cells and dermal macrophages. Of these, Langer-
an cells supported the highest virus growth titers. Parallel ﬁndings
ere made in intra-dermally infected mice, where DENV-infected
ermis DCs migrated to the skin-draining lymph nodes. In con-
rast, infection of lymph-node-resident DCs was negligible. These
ata indicate variability in the range of human skin antigen pre-
enting cells that can be infected with DENV and highlight the
otential double-edged sword of infected cells trafﬁcking to the
raining lymph nodes; this process enables an adaptive anti-viral
mmune response but plausibly helps facilitate systemic spread of
ENV. Consistent with these previous data, Schmid et al. [3] used
 murine model to identify that DENV infection occurs in resident
ermis DCs and macrophages, followed by infection of monocytes
nd moDCs that are recruited from the bloodstream to the der-
is, probably via chemoattractant molecules released at the site of
nfection. Collectively these data help to deﬁne the permissivenesshases in the evolution of dengue.
of dermis-resident antigen presenting cells to DENV infection, but
its uncertain if these artiﬁcial experimental systems reﬂect the nat-
ural history of DENV infection of humans. Thus, whilst some level
of dermis infection may  indeed be a common outcome after suc-
cessful (or unsuccessful) probing by a female Aedes mosquito, there
is no evidence that it is a pre-requisite for the systemic infection
that characterizes dengue. Instead, direct introduction of infectious
virions into the lumen of capillaries that are expertly breached by
the mosquito proboscis, followed by almost immediate systemic
spread of virus and infection of permissive cells in the largest vas-
cularized lymphoid tissue, the spleen, seems a more parsimonious
explanation for how successful, systemic DENV infection is initiated
in most cases.
3. Recent advances in understanding cellular immune
responses to dengue virus infection
3.1. The role of T cells
T cells, and in particular cross-reactive memory T cells recalled
during secondary heterotypic infections, have been nominated as
contributing to the clinical pathogenesis of dengue. This hypothesis
is based on the observation that T cells having surface and func-
tional phenotypes indicative of antigen-driven activation are more
abundant in early convalescence in children/adults with severe
dengue versus those with milder disease [4–6]. T cell responses can-
not however explain the pathogenesis of severe dengue in infants
with primary infection and thus there is particular context to the
“T cell hypothesis”. Stronger evidence, for or against, a mechanis-
tic role for DENV-reactive memory T cells in the severe clinical
complications of dengue is needed to help guide therapeutic inter-
vention strategies. Similarly, a better understanding of how T cells
might contribute to protection from re-infection is needed for the
advancement of vaccine development and identiﬁcation of immune
correlates. Recent advances in understanding the targets of DENV-
speciﬁc T cell responses, their functional phenotypes and their
tissue tropisms goes some way  to providing the tools to acquire
stronger mechanistic insights into their role in pathogenesis and
immunity.
3.2. CD8+ T cell responses: their targets and phenotypesSubstantial new data has been acquired on the targets of T cell
responses after natural infection. Rivino et al. [7] conﬁrmed and
expanded upon previous work in determining that CD8(+) T cell
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pitopes are predominantly located in the nonstructural proteins
S3 and NS5. Similarly Weiskopf et al. [8] identiﬁed DENV-reactive
D8+ T cell responses in Sri Lankan blood donors; 408 immunoreac-
ive peptides were identiﬁed, two thirds of which were located in
S3, NS5 or NS4b. Finally, following tetravalent vaccination with
ive attenuated DENV, Weiskopf et al. [9] demonstrated CD8+ T
ell responses were universally (99.8%) against non-structural pro-
eins, with 97% directed toward NS3 and NS5. Collectively, these
ata underscore the importance of DENV non-structural proteins
s CD8+ T cell immunogens during natural infection; this remains
n important consideration for vaccine strategies that, along with
nduction of neutralizing antibody, also seek to induce CD8+ T cell
emory.
Whether DENV-reactive CD8+ T cell responses contribute mech-
nistically to vascular leakage, the hallmark of severe dengue,
emains unresolved. Based on observations of HLA-A*11-restricted
D8+ T cell responses to the NS3133–142 epitope, Mongkolsapaya
t al. [10] have suggested original antigenic sin occurs amongst
D8+ T cell populations during secondary heterotypic infection.
et these conclusions have been drawn from observations made
n early convalescence, when CD8+ T cell responses peak, and not
uring the febrile and critical phase, when vascular leakage com-
ences and is most prominent. Indeed, Dung et al. [11] reported
hat NS3133–142-speciﬁc T cells were undetectable until after the
evelopment of plasma leakage among infected Vietnamese chil-
ren. In contrast, Freiberg et al. [12] detected very low frequencies
f activated NS3133–142-speciﬁc CD8+ T cells during the febrile
hase in both primary and secondary dengue cases, but found
o evidence that these responses correlated with immune sta-
us exposure or current disease severity. Although traditionally
easured in the blood, Rivino and colleagues [13] also identiﬁed
ighly activated and proliferating NS3133–142-speciﬁc CD8+ T cells
n experimentally induced skin blisters on dengue cases. Whether
hese dermis-inﬁltrating CD8+ T cells are relevant to pathogenesis
f the clinical and laboratory features of dengue is uncertain.
The next phase of research into CD8+ T cells and pathogenesis
eeds to take an expansive approach to measuring epitope-speciﬁc
 cells (e.g. using panels of Class I tetramer reagents, targeting more
han one speciﬁcity) and investigate responses longitudinally in the
hree phases of disease; early febrile, critical phase and convales-
ence, with sample sizes large enough to capture the spectrum of
linical outcomes, from the very mild to the severe. These are chal-
enging studies to perform but are necessary if the ﬁeld is to advance
he understanding of CD8+ T cells in pathogenesis and immunity.
.3. CD4+ T cells responses: their targets and phenotypes
In contrast to CD8+ T cell responses, DENV-speciﬁc CD4+ T
ells have been less well characterized. In patients with secondary
engue, Rivino et al. [7] demonstrated that CD4+ T cell epitopes are
redominantly located in structural proteins e.g. envelope, capsid,
nd NS1, which themselves are major targets of the B cell response.
irculating CD4+ T cells during early convalescence had the surface
nd functional phenotype of follicular helper T cells, suggesting that
hey are interacting with B cells in vivo, presumably to assist anti-
ody production. Whether the size of the acute expansion of the
ollicular helper T population in blood is predictive of the anti-
ENV neutralizing Ab titer deserves investigation as a possible
mmune correlate of vaccine or infection-driven humoral immune
esponses. Mangada et al. [14] examined CD4+ cells in 6 donors who
ad received monovalent live attenuated DENV vaccine 12 months
rior. Stimulation with heterologous serotype peptide resulted in
ore TNF-producing cells than IFN producers relative to stimu-
ation with homologous peptides, suggesting differential functional
henotypes amongst these cell populations that are dependent on
he type of antigenic stimulation. This repeats a theme also evident33 (2015) 7061–7068 7063
in studies of CD8+ T cells, that partial peptide agonists elicit a
diverse range of functional phenotypes in cross-reactive T cells [15].
In a mouse model, Yauch et al. [16] identiﬁed that DENV2-speciﬁc
CD4+ T cells were of a Th1 phenotype and could mediate in vivo
cytotoxicity and that immunization with dominant CD4+ T cell epi-
topes led to enhance viral clearance. Whether results in murine
models are informative for understanding human immunization or
disease remains uncertain, but these results underscore the need
for further investigations of CD4+ T cells in dengue pathogenesis.
3.4. Mast cells
Mast cells (MCs), whilst traditionally associated with hyper-
sensitivity responses, express a wide range of Fc receptors and
hence are candidates for involvement in dengue pathogenesis. St
John et al. demonstrated in a mouse model that MCs  are activated
in vivo during experimental DENV infection and MC-deﬁcient mice
had greatly reduced vascular leakage compared to MC-sufﬁcient
controls. Treatment of experimentally infected animals with MC-
stabilizing drugs also ameliorated vascular leakage [17]. In humans,
MC-derived vasoactive products such as chymase, a serine pro-
tease, are elevated in the peripheral blood of primary and secondary
dengue cases [17,18]. As attractive as MCs  might be as “actors” in
the pathogenesis of severe dengue, there remain critical questions.
For example, to explain the clinical observation that secondary
heterotypic DENV infection is associated with greater risk of severe
disease, the “MC  hypothesis” requires some level of Ab-Ag, (e.g.
viral particles or NS1) to trigger Fc receptor aggregation on MCs
and their activation/degranulation; this has yet to be shown in a
convincing fashion. Moreover, the timing of MC activation would
need to occur in a manner temporally consistent with the evolution
of vascular leakage, i.e. most pronounced leading up to the time of
defervescence in severe cases [19]. Thus, whilst MCs  are intrigu-
ing, further clinical studies, possibly even drug probe studies, are
needed to better understand their contribution to human disease.
3.5. Humoral immunity
Antibodies are believed to be critical mediators of resolution of
infection, immunity to reinfection and in some circumstances, are
believed to be risk factors for severe disease, i.e. antibody depend-
ent enhancement (ADE) of infection. Recent results of phase IIb
and III clinical trials of Sanoﬁ Pasteur’s recombinant live atten-
uated tetravalent dengue vaccine (CYD-TDV) have questioned
the decades-old assumption that plaque reduction neutralization
assays (PRNT50) are good predictors of immune status. Speciﬁ-
cally, CYD-TDV elicited tetravalent virus neutralizing antibodies
after three doses yet offered very low levels of efﬁcacy against
DENV-2 and modest efﬁcacy against DENV-1 [20,21]. That the rela-
tionship between PRNT50 titer and immunity to DENV-2 is complex
were reinforced by Buddhari et al. [22] who utilized data from geo-
graphic cluster studies in Thailand. They found an overall signiﬁcant
positive association between baseline PRNT50 titers to DENV-1, -2
and DENV-4 and immunity from homotypic symptomatic infection
during the follow-up period. However the threshold for deﬁning
immunity to DENV-2 was unclear and might be higher than for
other serotypes. Thus, traditionally accepted PRNT50 values (i.e.
titer >10) regarded as denoting “immunity” to DENV may  not
be accurate, especially so for DENV-2. This has provided motiva-
tion to the ﬁeld to explore alternative correlative assays. This is
being enabled in part by productive basic research that has iden-
tiﬁed new, highly potent virus-neutralizing human mAbs elicited
by natural infection. Mapping the epitope targets of these mAbs
has revealed many target quaternary epitopes on the virus sur-
face [23–25]. Some are serotype speciﬁc (e.g. 14C10 targeting
DENV-1 [26] and 5J7 that targets DENV-3 [24]) whilst others are
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ross-reactive (e.g. the so-called Envelope Dimer Epitope mAbs
7 and C10) [27]. The existence of rare but potently neutraliz-
ng, cross-reactive human mAbs elicited by natural infection is
rovocative. Potentially, such Abs, and their epitope targets, could
e deployed for pan-serotype therapeutic indications or vaccine
evelopment efforts. Additionally, these mAbs could be used for
evelopment and/or validation of 2nd generation virus neutraliza-
ion assays that replace or augment the PRNT50 measurement. For
xample, 2nd generation assays might compete individual or pan-
ls of highly potent virus neutralizing mAbs with polyclonal sera
rom vaccinees for binding to viral particles or recombinant pro-
eins and thus determine a titer of antibodies in polyclonal sera
peciﬁc for the critical epitope regions on the virus. Finally, for
accine development, it is likely that strategies employing DENV
nvelope protein subunits as immunogens will fail to elicit some
f these quaternary epitope binding immune responses; whether
his signiﬁcantly reduces the probability of success of this vaccine
trategy is unknown.
.6. Immune subversion
A recent expert review has reported the latest mechanistic
nderstanding of how DENV manipulates intracellular antiviral
esponses and directly inhibits cellular signaling cascades in order
o favor its own replication [28]. Here, we will focus on the role
f lipids, and induction of the autophagy and endoplasmic reti-
ulum (ER) stress pathways during DENV infection. Intracellular
eplication of DENV occurs on the cytoplasmic side of remodeled
R membranes and requires sufﬁcient lipid resources from the host
ell to enable efﬁcient encapsidation and assembly of virions.
Recent evidence suggests lipid droplets and the autophagy
athway positively contribute to the pool of lipid resources that
nables DENV genome encapsidation and assembly [29,30]. Hence
utophagy, sometimes regarded as a biochemical arm of the innate
nti-viral immune response, actually beneﬁts DENV replication.
dditionally, cholesterol has been shown to play a pivotal role
n the replication cycle of DENV and other ﬂaviviruses, contribut-
ng not only to efﬁcient replication but also to immune evasion
31–33]. Although, the mechanism by which dengue regulates lipid
omeostasis and recruitment for these purposes is not currently
nderstood, the membrane remodeling protein NS4A appears
o be a likely candidate [34,35]. In addition to autophagy it is
bserved that all ﬂaviviruses modulate the ER stress/unfolded pro-
ein response. DENV, JEV and WNV  all activate Xbp-1, ATF6 and IRE1
egulatory factors to promote cell survival and immune evasion
36–41]. Although the exact underlying molecular and functional
spects of this induction are not currently understood it is pertinent
o highlight that Xbp-1 can promote lipid biosynthesis [42], IRE1
s involved in regulated RNA decay pathway promoting anti-viral
efense [43] and ATF6 can regulate activation of innate immune
esponses and cell death [44]. Thus there appears to be an inte-
rated involvement of autophagy and ER stress/UPR modulation to
romote lipid balance, intracellular replication and survival. Given
he seemingly central role for these cellular responses in DENV
eplication key enzymes or by-products within these pathways are
ttractive candidates for antiviral therapeutics.
.7. Recent advances in understanding virological determinants
f DENV transmission
Whilst humans are dead-end hosts for many Flaviviruses, the
ynamics of human-to-mosquito transmission of DENV has been
entral to its successful emergence. Accumulated data from empir-
cal infection studies on human subjects conducted in the ﬁrst half
f the twentieth century showed that humans can be infectious to
osquitoes from 1.5 days prior to the onset of symptoms to around33 (2015) 7061–7068
5 days after the commencement of symptoms [45–49]. Recent stud-
ies have quantiﬁed the factors shaping transmission to either Aedes
aegypti or Ae. albopictus.  In infected humans, the concentration of
virus circulating in the blood, and the duration that it circulates,
inﬂuences the likelihood of a permissive Aedes mosquito becom-
ing infected after imbibing a blood meal [50,51]. Nguyet et al. [50],
and separately Whitehorn et al. [51] experimentally measured the
plasma viremia characteristics in Vietnamese adult dengue cases
that led to DENV infection of directly blood-fed Aedes aegypti or Ae.
albopictus. For Ae. aegypti, the plasma viremia required to infect 50%
of mosquitoes differed between serotypes and was ∼10-fold lower
for DENV-1 and DENV-2 (6.29 or 6.51 log10 RNA copies/ml) than
for DENV-3 and DENV-4 (7.49 or 7.52 log10 RNA copies/ml). For
Ae. albopictus the 50% mosquito infectious dose was highly similar
to that in parallel-fed Ae. aegypti, suggesting equal permissiveness
between these species for initial infection of midgut tissues. In
addition, Nguyet et al. [50] demonstrated that patients with a high
early viremia have a longer window of infectiousness to Ae. aegypti.
Collectively, these ﬁndings deﬁne the viremia level that interven-
tions such as vaccines and antivirals must target for prevention or
amelioration to reduce DENV transmission.
3.8. The evolving story of NS1
More than 40 years ago, a series of papers described a sol-
uble complement ﬁxing (SCF) antigen in dengue virus infected
mice and cell culture [52–54]. This SCF antigen was identiﬁed as
a secreted non-structural viral protein [55] that was later desig-
nated NS1, following the sequencing of the ﬁrst ﬂavivirus genome
[56]. It was immediately seen as a potential player in the pathogen-
esis of severe disease primarily because of the reported association
between high levels of complement consumption and dengue
shock syndrome (DSS) [57]. These studies lead to an expansion of
interest in the role of complement pathway engagement by dengue
viruses in infected patients and in particular, the role of immune
complexes in potentiating the severity of disease [53,58–61]. How-
ever, the underlying in vivo mechanism of complement activation
and the role of secreted NS1 has remained a matter of conjec-
ture ever since. The development of NS1 capture assays [62,63]
and the discovery that high levels of circulating NS1 in patient
sera early during the course of infection correlate with progres-
sion to severe disease [64,65] has provided further impetus to
research in NS1 as a mediator of disease. These studies have lead
to a greater understanding of the structure and trafﬁcking of this
protein within and from infected cells, its proposed role in viral
replication, potential as a vaccine candidate, value in diagnos-
tic applications and its role in pathogenesis in vivo through its
interaction with an ever increasing number of host cell targets
(reviewed in Muller and Young [66]). Not surprisingly, these host
cell binding partners have been shown to comprise a number of
different complement pathway components in addition to other
host cell regulatory proteins. These include the complement regu-
lation protein factor H (fH), complement inhibitory factor clusterin,
complement proteins C4 and proC1s/C1s, hnRNP C1/C2, STAT3,
thrombin/prothrombin and has been shown to trigger the gener-
ation of C5b-9 and SC5b-9 complexes [66]. The recent publication
of the crystal structure of both dengue and WNV  NS1 has provided
some clues into the structural basis of NS1-host cell protein engage-
ment [67]. Both dimer and hexamer forms of NS1 reveal three
distinct structural domains, a hydrophobic -roll (residues 1–29),
an /-wing (residues 38–151; comprising a RIG-I like fold) and a
central -ladder (residues 181–352). These are all connected via a
3-stranded -sheet (residues 30–37 and 152–180). The hydropho-
bic N-terminal -roll, along with a hydrophobic loop extension
from the connector (residues 159–162) provide a hydrophobic face
to the dimeric form, thereby explaining membrane association of
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his otherwise hydrophilic protein as well as its ability to assem-
le as a hexameric lipoparticle that carries a lipid cargo. The RIG-I
ike wing domain is intriguing as it suggests that NS1 may  act as
n RNA sensor, interacting with dsRNA recognition systems of the
nnate immune response. However RIG-I is located in the cytoplasm
f cells, on the opposite side of the ER membrane to NS1 and so
ow it could operate in this way is unknown. Akey et al. [68] have
peculated that the wing domain may  interfere with RLR-dsRNA
ignaling. Perhaps the most revealing structural insight has come
rom comparisons with crystal structures of complement compo-
ents bound to other pathogen proteins [68]. A common feature
f these structures is the association of anti-parallel -sheets from
he pathogen proteins with the conserved complement control pro-
ein (CCP) domain of their complement partners. The CCP domain is
ound in factor H, C1s, C4 and C4 binding proteins, all demonstrated
inding partners of NS1. The -roll and -ladder are clearly can-
idates for the NS1 domains responsible for complement protein
inding. Mutagenesis and binding studies should quickly reveal the
otential in vivo role for these interactions.
.9. Clinical management
Until such time as safe and effective vaccines are available and
outinely deployed in endemic countries, ensuring good clinical
utcomes for individuals with symptomatic dengue must rely on
 combination of early case detection and prompt and appropri-
te case management, allied with close follow-up to identify and
reat severe manifestations as soon as they occur. However, since
engue shares clinical features with a wide variety of illnesses
specially during the early febrile phase, large numbers of patients
ith possible dengue are often admitted to healthcare facilities in
ndemic areas, primarily for observation, and seasonal epidemics
ay  overwhelm health service capacity. Improvements in clini-
al diagnosis of dengue and risk prediction for severe disease are
rgently needed, especially in settings with a high case burden
here appropriate allocation of limited resources is crucial to out-
ome.
.9.1. Improving clinical diagnosis and risk prediction
As noted earlier the clinical presentation of dengue varies
idely. While the majority of symptomatic patients recover after
 short illness, a small proportion progress to more severe dis-
ase, typically manifesting as a vasculopathy characterized by
lasma leakage and a hemorrhagic diathesis. Plasma leakage
ay  be profound, particularly in children, sometimes resulting in
ife-threatening dengue shock syndrome (DSS). Other severe com-
lications do occur, particularly severe liver and/or neurological
nvolvement, but are less frequent. The 2009 World Health Orga-
ization (WHO) revised classiﬁcation system deﬁnes two  major
ntities, dengue and severe dengue, in place of the more complex
engue fever/dengue hemorrhagic fever categories previously rec-
mmended [69] Although the revised classiﬁcation is more easily
pplicable for clinical and epidemiological purposes, debate contin-
es regarding the utility of both systems for pathogenesis research
70–72]; however efforts are on-going within the international
engue research community to develop agreed standards for the
etailed discrimination of dengue clinical phenotypes for use in
athogenesis studies and/or therapeutic intervention trials.
Given the protean manifestations of clinical dengue, it is clear
hat observational studies need to be very large to allow meaningful
nterpretation of the relative importance of different clinical fea-
ures. In one recent study that enrolled more than 5000 Vietnamese
hildren presenting within 72 h of fever onset with clinically sus-
ected dengue [73] of whom 1692 were subsequently conﬁrmed to
ave dengue, a diagnostic algorithm using the patient’s age, total
hite cell count and platelet count at presentation, resulted in33 (2015) 7061–7068 7065
sensitivity and speciﬁcity of around 75% for diagnosis of dengue.
Inclusion of additional clinical and routine laboratory data did not
improve signiﬁcantly on the performance characteristics of the
Early Dengue Classiﬁer, but use in conjunction with an NS1 rapid
test improved the sensitivity to over 90%. However it is notable
that this classiﬁer would only be relevant in similar epidemiologi-
cal settings with a high burden of pediatric dengue cases. A second
major prospective dataset describing the clinical features and man-
agement for over 1700 Vietnamese children with DSS  admitted
to a single hospital [19], has also been published recently; clini-
cal signs and symptoms were generally consistent with empirical
descriptions of DSS, although at presentation 9% of cases were still
febrile and almost one-third had no bleeding during the entire ill-
ness episode. Only 8 patients died, conﬁrming that with prompt,
assiduous clinical care by experienced staff the outcome of this
potentially fatal condition can be excellent. These data were also
used to develop a prognostic model to identify patients at risk of
developing profound or recurrent shock [74]. Earlier presentation
with DSS, and more severe hemodynamic compromise at presen-
tation, were also identiﬁed as important risk factors for recurrent
shock in the only other published study to examine this issue [75],
which used data collected from 444 children managed at two  other
healthcare facilities in southern Vietnam. The other risk factors
identiﬁed differed between the two  studies, highlighting the fact
that elements of study design including study deﬁnitions, timing
of observations in a disease with a rapidly evolving natural history,
sample size, etc., can affect the comparability and generalizability
of research ﬁndings in the wider context.
The ability to identify, during the febrile phase, patients at
high risk of progression, i.e. those likely to beneﬁt from admis-
sion for close observation and early intervention with supportive
therapy, has become the focus of intense research effort in recent
years. The 2009 classiﬁcation encompasses a set of ‘warning signs’,
derived in part from a dataset describing almost 2000 patients with
dengue recruited across Asia and Latin America [76]. However, a
major limitation of this and all other related research published
to date has been the limited number of patients who  have devel-
oped severe disease while under detailed observation. Recognizing
this limitation, and the importance of providing a clear evidence-
base for any future reﬁnement of the WHO  guidelines, a major
clinical study is presently underway, coordinated by one of the
three large EU funded consortia that are currently working on
dengue research themes [77]. The study aims to recruit 8–10,000
outpatients of all ages, presenting with possible dengue at sites
across 9 endemic countries within the ﬁrst 3 days of fever (Clin-
icalTrials.govID: NCT01550016. www.idams.eu). Participants are
followed daily to identify readily available clinical and laboratory
parameters, and/or viral and immunological markers, that differ-
entiate between dengue and other common febrile illness, and
secondly to identify any features that predict likely progression to
a more severe disease course. Almost 6000 participants have been
recruited to date, and the study is expected to report toward the
end of 2016. It is to be hoped that with this very large patient cohort,
clinical and/or laboratory warning signs with high predictive power
can be identiﬁed. In addition, while previous efforts have always
used data collected at a single time-point to assess risk, this dataset
makes it possible to evaluate the evolution of particular symptoms
or laboratory values over time for their utility in risk prediction.
3.9.2. Therapeutic interventions
Current management strategies continue to focus on support-
ive care [78]. Individual case-management relies largely on careful
monitoring to recognize vascular leakage and provide judicious
ﬂuid replacement, combined with prompt volume resuscitation
for patients who do develop DSS. Regrettably no formal research
to establish an evidence-base to support these ﬂuid resuscitation
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ecommendations has taken place for 10 years [79], likely reﬂecting
he practical difﬁculties inherent in such trials, as well as the very
arge sample sizes that would be required and the ﬁnancial cost.
owever, given the on-going controversy surrounding ﬂuid resus-
itation in critical care generally [80,81], there is a clear need to
ddress these difﬁculties [82]. On the other hand, in the face of the
ver-increasing burden of dengue globally [83], the development
f speciﬁc therapeutic interventions directed toward symptomatic
engue, rather than DSS speciﬁcally, has become a major focus of
urrent research efforts.
First, there is considerable interest in the potential utility of
ntiviral agents. An effective and safe antiviral therapy, if given
rally to outpatients with dengue, might be expected not only to
ecrease the burden on healthcare services in endemic areas, but
otentially might also reduce on-going transmission of the virus to
osquitoes and new human hosts. Compounds that target a num-
er of possible virus and host proteins are in development, but only
 few agents have so far been assessed in formal clinical trials in
engue-infected humans [84]. These include chloroquine, balapi-
avir (a polymerase inhibitor developed for treatment of the related
irus, hepatitis C) and celgosivir (a cellular glucosidase inhibitor)
85–87]. Unfortunately, although the safety assessments were gen-
rally satisfactory, there was no evidence in any of these trials of
 beneﬁt in reducing plasma viremia or in preventing the devel-
pment of complications. Subsequent investigation of the lack of
esponse to balapiravir has indicated that dengue virus infection
ikely limits conversion of the prodrug to the active moiety [88]. It
s also noteworthy that all three trials were conducted in southeast
sian adults, a population at relatively low risk for complications;
o power any subsequent trials in similar populations to a robust
linical efﬁcacy endpoint would likely require enrolment of sev-
ral thousand patients, so the development of reliable algorithms
o identify high-risk patients could greatly facilitate the conduct of
uch trials in the future.
An alternative intervention strategy involves suppression of the
ost immune response. A number of small clinical trials have exam-
ned the efﬁcacy of corticosteroids in patients with DSS, but with
nconsistent results. However most of the work was carried out
ver 25 years ago, and the studies were underpowered and lacked
tringent randomization or allocation concealment [89]. Notably
lso, the steroids were administered after onset of shock, which
s likely to be too late in the disease evolution to exert a ben-
ﬁcial effect. An alternative strategy involves early intervention
uring the febrile phase in an attempt to prevent or attenuate
evere disease. One randomized, blinded, placebo-controlled clin-
cal trial of early prednisolone was recently conducted in Vietnam
n 225 children with conﬁrmed dengue, with the primary goal of
ssessing safety during the phase of active viral replication [90].
ther than a trend to hyperglycaemia in high-dose steroid recipi-
nts the trial showed no evidence of harm with early prednisolone
se compared to placebo, but there was also no evidence of efﬁ-
acy in preventing DSS. Prednisolone conferred only a small change
n the whole blood gene expression proﬁle, with only 81 trans-
ripts from 64 genes differentially abundant between high-dose
rednisolone and placebo recipients [91]. Secondly, no attenuation
f early-convalescent T cell responses or plasma cytokine levels
as observed. Overall the inﬂuence of prednisolone on immune
esponse parameters in dengue patients was minimal, in line with
he trial evidence showing lack of impact on clinical laboratory end-
oints or the clinical phenotype. One possible explanation could
e that even commencing prednisolone therapy within the ﬁrst
2 h is too late to attenuate the infection-driven processes that
ead to the development of complications. Use of higher dose
herapy might be considered as an option, but given the trend
o hyperglycemia among participants receiving the 2 mg/kg pred-
isolone dose, it is unlikely that clinicians would consider this an33 (2015) 7061–7068
acceptable risk to take with a treatment likely to be administered to
large numbers of patients in the community. Interestingly, the fail-
ure of prednisolone to show a beneﬁt in either clinical or laboratory
outcomes for dengue patients leaves the door open for the hypoth-
esis that mast cell mediators play a role in dengue pathogenesis as
corticosteroids have no effect on mast cell degranulation [92].
Another agent that is under active investigation as a ther-
apeutic for dengue is lovastatin, one of the statin group of
lipid-lowering drugs. Additional to their well-established role in
cardiovascular risk modiﬁcation [93], statins are recognized to have
anti-inﬂammatory and endothelial-stabilising properties. Retro-
spective studies have suggested potential beneﬁt from adjunctive
statin therapy in severe sepsis [94], although in more recent for-
mal  randomized controlled trials statin use did not improve clinical
outcomes in patients with sepsis-associated Acute Respiratory Dis-
tress Syndrome or reduce exacerbations of chronic obstructive
pulmonary disease [95–97]. Given that endothelial dysfunction is
one of the deﬁning features of severe dengue, and that, in addition
to its immunomodulatory properties, lovastatin has been shown
to inhibit dengue virus replication in vitro [98], a randomized
placebo-controlled trial to evaluate the safety and tolerability of
early lovastatin therapy in 300 Vietnamese adults with dengue was
initiated in 2011 (ISRCTN03147572) [99]. The trial is expected to
report shortly.
Finally, the results of the Adult Dengue Platelet Study (ADEPT,
ClinicalTrials.gov: NCT01030211), a prospective randomized open-
label trial to examine the safety and efﬁcacy of prophylactic
platelet transfusion in Singaporean adults with severe dengue-
related thrombocytopenia (platelet count below 20,000/l) but no
bleeding, are also likely to be published shortly. Thrombocytopenia
is frequently observed in patients with dengue, but is rarely accom-
panied by clinically relevant bleeding. Prophylactic transfusion of
platelets is common however [100–102], despite a lack of evidence
of beneﬁt, signiﬁcant cost, and the acknowledged risks of ﬂuid over-
load, allergic reactions and transmission of blood–borne pathogens.
A recent publication from Pakistan describing a randomized open-
label study of 87 patients with dengue and a platelet count below
30,000/l [103], concluded that administration of platelets did not
prevent development of severe bleeding or shorten the time to ces-
sation of bleeding, but was associated with signiﬁcant harm. If the
results of the ADEPT trial, with a larger sample size and a more strin-
gent platelet cutoff, prove to be similar, it is to be hoped that this
evidence will be rapidly incorporated into international and local
management guidelines, so as to inform rational decision-making
on this important aspect of supportive care for dengue patients.
4. Conclusions
Unquestionably, the phase III vaccine clinical trial results of
CYD-TDV have reminded the research community that there is
still much to learn with regards to understanding induction and
expression of immunity to DENV. Further, there remain knowledge
gaps in clinical pathogenesis that preclude a wider, evidence-based
spectrum of therapeutic strategies for improved case management.
Focused research efforts on these critical bottlenecks will hopefully
lead to improvements in disease prevention and management in
the next decade.
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